## SWK Holdings to Present at Maxim Group's Emerging Growth Virtual Conference

DALLAS, March 15, 2021 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that Winston Black, Chairman and CEO of SWK Holdings, will present during the Maxim Group Emerging Growth Virtual Conference taking place Wednesday, March 17 to Friday, March 19, 2021.

In a prerecorded presentation, available on demand to all registered conference attendees, Mr. Black will provide an overview of SWK Holdings' business and investment strategy, and highlight recent corporate achievements, as well as anticipated milestones. Mr. Black will also participate in a live "fireside chat" hosted by Mike Diana, Managing Director at Maxim Group.

Details of SWK Holdings' presentations are as follows:

**Event:** 2021 Emerging Growth Virtual Conference **Date:** Wednesday, March 17 to Friday, March 19, 2021

**Registration:** https://www.m-vest.com/events/2021-emerging-growth-virtual-conference

Fireside Chat: Friday, March 19 12 Noon ET

Mr. Black will also host virtual one-on-one meetings with investors and potential portfolio partners.

The presentation webcast will be available on the Investor Relations section of the SWK Holdings website at <a href="https://swkhold.investorroom.com/events">https://swkhold.investorroom.com/events</a> following the conference.

## **About SWK Holdings:**

SWK Holdings Corporation is a specialized finance company with a focus on the global healthcare sector. SWK partners with ethical product marketers and royalty holders to provide flexible financing solutions at an attractive cost of capital to create long-term value for both SWK's business partners and its investors. SWK believes its financing structures achieve an optimal partnership for companies, institutions and inventors seeking capital for expansion or capital and estate planning by allowing its partners to monetize future cash flow with minimal dilution to their equity stakes. SWK also owns Enteris Biopharma, whose core Peptelligence ™ drug delivery technology creates oral formulations of peptide-based and BCS class II, III, and IV small molecules. With Enteris, SWK has the opportunity to grow its specialty finance business by actively building a wholly-owned portfolio of milestones and royalties through licensing activities. Additional information on the life science finance market is available on the Company's website at <a href="https://www.swkhold.com">www.swkhold.com</a>.

## **Safe Harbor Statement**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect SWK's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" and elsewhere in SWK's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein, could affect the Company's future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the Company's actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

**SOURCE SWK Holdings Corporation** 

For further information: Jason Rando (Media), +1.212.375.2665, jrando@tiberend.com; Maureen McEnroe, CFA (Investors), +1 212.375.2664, mmcenroe@tiberend.com